HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
September 18, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's stock may see positive movement due to the reiterated 'Buy' rating and maintained price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence a stock's performance. The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Innate Pharma, which could positively impact the stock's short-term price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100